Drug maker, Lupin said that it has received approval for Bepotastine tablets from the Central Drugs Standard Control organisation (CDSCO).
The promotion for the same product is going to commence in India shortly, informed the company in a Bombay Stock Exchange (BSE) filing.
Bepotastine is a new second generation antihistamine medicine to be introduced into the Indian Pharmaceutical Market (IPM) which could benefit patients suffering from allergic symptoms.
It is a rapid acting antihistamine that controls day time and night time triggers of allergic symptoms, and is actively marketed in Japan and other South East Asian countries.
Commenting on the development, Dr Naresh Gupta, President, Lupin said, “I am sure that the approval of Bepotastine would go a long way in addressing a common medical need for a safe and effective drug for the management of allergic symptoms.”
According to IMS MAT, the current market for plain antihistamines is estimated to be around Rs 860 crore growing at 14 percent during March 2017.
Meanwhile, shares of the company were trading at Rs 1269.9 apiece, down 3.42 per cent from the previous close at 12:05 hours on BSE.